Defibrillation in acute myocardial infarction trial

DINAMIT = Defibrillator in Acute Myocardial Infarction Trial. 

The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT) enrolled nearly 700 patients with recent MI, ranging from 6 to 40 days (median 7 days), EF < 36%, and reduced heart rate variability but without NYHA class IV symptoms, sustained VT within 48 h of MI, or surgical or percutaneous 3-vessel revascularization [34]. Patients were randomized to ICD therapy versus conventional therapy and at 1 year, there was no difference in total mortality with more arrhythmic deaths in the control arm and more nonarrhythmic deaths in the ICD arm. Thus, there appears to be no benefit to ICD therapy in the immediate post-MI period. An interpretation of the negative result of both of these trials is that significant recovery of LV function may have occurred in the... 

Arguably, ICDs for primary prevention has greater benefit for the entire population than ICDs for secondary prevention. Several key primary prevention trials have been completed M IT, MUSTT, CABG-Patch (Coronary Artery Bypass Graft surgery), MADIT II, DINAMIT (Defibrillator in Acute Myocardial Infarction Trial), DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation), SCD-HeFT, CAT (CArdiomyopathy Trial), and AMIOVERT (AMIOdarone VERsus implanv cardioverTer-defibrillator) trials (Table 14.4) (54,119,172-174). 

---